Abbott Laboratories Future Growth

Future criteria checks 4/6

Abbott Laboratories is forecast to grow earnings and revenue by 11.5% and 6.6% per annum respectively. EPS is expected to grow by 11.6% per annum. Return on equity is forecast to be 22% in 3 years.

Key information

11.5%

Earnings growth rate

11.6%

EPS growth rate

Medical Equipment earnings growth	18.9%
Revenue growth rate	6.6%
Future return on equity	22.0%
Analyst coverage	Good
Last updated	17 Oct 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

WBAG:ABT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	48,222	7,771	9,248	N/A	23
12/31/2025	44,936	6,842	8,818	N/A	25
12/31/2024	42,007	5,922	9,102	N/A	22
9/30/2024	41,217	5,745	N/A	N/A	N/A
6/30/2024	40,725	5,535	5,654	7,900	N/A
3/31/2024	40,326	5,608	4,923	7,143	N/A
12/31/2023	40,109	5,701	5,059	7,261	N/A
9/30/2023	39,959	5,153	4,492	6,549	N/A
6/30/2023	40,226	5,151	5,488	7,452	N/A
3/31/2023	41,505	5,785	6,823	8,659	N/A
12/31/2022	43,653	6,905	7,804	9,581	N/A
9/30/2022	45,030	7,857	8,541	10,322	N/A
6/30/2022	45,548	8,520	8,468	10,243	N/A
3/31/2022	44,514	7,695	8,152	9,961	N/A
12/31/2021	43,075	7,042	8,648	10,533	N/A
9/30/2021	42,308	7,208	9,314	11,264	N/A
6/30/2021	40,233	6,343	8,644	10,629	N/A
3/31/2021	37,338	5,693	7,609	9,823	N/A
12/31/2020	34,608	4,449	5,724	7,901	N/A
9/30/2020	32,221	3,346	4,587	6,519	N/A
6/30/2020	31,444	3,073	4,564	6,401	N/A
3/31/2020	32,095	3,539	4,476	6,139	N/A
12/31/2019	31,904	3,666	4,498	6,136	N/A
9/30/2019	31,355	3,272	3,814	5,485	N/A
6/30/2019	30,935	2,867	4,096	5,720	N/A
3/31/2019	30,723	2,582	4,450	5,904	N/A
12/31/2018	30,578	2,319	4,906	6,300	N/A
9/30/2018	30,402	802	4,903	6,175	N/A
6/30/2018	29,575	812	N/A	5,997	N/A
3/31/2018	28,445	365	N/A	6,104	N/A
12/31/2017	27,390	344	N/A	5,570	N/A
9/30/2017	25,134	1,971	N/A	5,100	N/A
6/30/2017	23,607	1,055	N/A	4,312	N/A
3/31/2017	22,303	1,384	N/A	3,870	N/A
12/31/2016	20,853	1,056	N/A	3,203	N/A
9/30/2016	20,708	989	N/A	2,861	N/A
6/30/2016	20,556	1,939	N/A	2,839	N/A
3/31/2016	20,393	2,124	N/A	2,871	N/A
12/31/2015	20,405	2,586	N/A	2,966	N/A
9/30/2015	20,573	2,523	N/A	3,376	N/A
6/30/2015	20,502	2,365	N/A	3,382	N/A
3/31/2015	20,389	2,004	N/A	3,341	N/A
12/31/2014	20,247	1,710	N/A	3,675	N/A
9/30/2014	19,905	1,560	N/A	4,062	N/A
6/30/2014	19,651	1,762	N/A	3,383	N/A
3/31/2014	19,034	1,654	N/A	3,200	N/A
12/31/2013	19,657	1,970	N/A	3,324	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABT's forecast earnings growth (11.5% per year) is above the savings rate (1.2%).

Earnings vs Market: ABT's earnings (11.5% per year) are forecast to grow faster than the Austrian market (7% per year).

High Growth Earnings: ABT's earnings are forecast to grow, but not significantly.

Revenue vs Market: ABT's revenue (6.6% per year) is forecast to grow faster than the Austrian market (-0.5% per year).

High Growth Revenue: ABT's revenue (6.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ABT's Return on Equity is forecast to be high in 3 years time (22%)

Abbott Laboratories Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Abbott Laboratories Provides Earnings Guidance for the Third-Quarter 2024

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Recent updates

Third quarter 2024 earnings released: EPS: US$0.94 (vs US$0.82 in 3Q 2023)

Abbott Laboratories (NYSE:ABT) announces an Equity Buyback for $7,000 million worth of its shares.

Abbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping

Upcoming dividend of US$0.55 per share

Abbott Laboratories to Report Q3, 2024 Results on Oct 16, 2024

Second quarter dividend of US$0.55 announced

Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression

Second quarter 2024 earnings released: EPS: US$0.74 (vs US$0.79 in 2Q 2023)

Abbott Laboratories Provides Earnings Guidance for the Third-Quarter 2024

Upcoming dividend of US$0.55 per share

Abbott Laboratories(NYSE:ABT) dropped from Russell 1000 Growth-Defensive Index

Abbott Laboratories to Report Q2, 2024 Results on Jul 18, 2024

Purchasers of Certain PediaSure Products in California May Have Their Rights Affected by a Class Action Lawsuit

First quarter dividend of US$0.55 announced

Abbott Teams Up with the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health

Abbott Laboratories Declares Quarterly Common Dividend, Payable on August 15, 2024

Insider recently sold €2.3m worth of stock

First quarter 2024 earnings released: EPS: US$0.70 (vs US$0.76 in 1Q 2023)

First quarter 2024 earnings released: EPS: US$0.70 (vs US$0.75 in 1Q 2023)

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Upcoming dividend of US$0.55 per share

Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

Abbott Receives FDA Approval for Triclip™, First-Of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott Laboratories to Report Q1, 2024 Results on Apr 17, 2024

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Announces Real-World Data Show Freestyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Fourth quarter dividend of US$0.55 announced

Abbott Declares Quarterly Cash Dividend, Payable on May 15, 2024

FDA Advisory Committee Votes in Favor of Abbott's First-Of-Its-Kind TriClip System to Treat People with a Leaky Tricuspid Heart Valve

Abbott Laboratories Announces the Launch of Its New PROTALITY Brand

Abbott Launches Smallest Rechargeable System with Remote Programming Capabilities to Treat Movement Disorders

Now 20% overvalued after recent price rise

Full year 2023 earnings released: EPS: US$3.27 (vs US$3.94 in FY 2022)

Abbott Laboratories Provides Earnings Guidance for the Full Year 2024

Abbott Laboratories Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott Laboratories Announces Quarterly Dividend Payable on Feb. 15, 2024

Abbott Announces New Late-Breaking Data That Show Advanced Heart Failure Patients Living with its HeartMate 3 Heart Pump

Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes

Now 20% undervalued after recent price drop

Abbott Laboratories Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV

Independent Director recently sold €4.5m worth of stock

Abbott Announces Late-Breaking Data from the LIFE-BTK Clinical Trial Evaluating the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System

Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

Third quarter 2023 earnings released: EPS: US$0.82 (vs US$0.81 in 3Q 2022)

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Upcoming dividend of US$0.51 per share at 2.1% yield

Now 21% undervalued after recent price drop

Abbott Laboratories to Report Q3, 2023 Results on Oct 18, 2023

Abbott Laboratories (NYSE:ABT) acquired Bigfoot Biomedical, Inc..

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies